This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

Development of an Atherogenic Metabolic Risk Factor Profile Associated With the Use of Atypical Antipsychotics.

James L. Karagianis, MD, FRCPC, and Eduardo Dunayevich, MD

Published: January 15, 2005

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: We read with interest the article by Alméras et al.1 reporting a worse metabolic risk profile in olanzapine-treated patients compared with risperidone-treated patients and a control group. While we agree with the authors on the need for research on this important topic, we believe the serious limitations to the methodology employed in this study significantly limit the interpretation and generalizability of their findings. First, the nonrandomized, cross-sectional design introduces likely bias in the selection of patients assigned to risperidone and olanzapine.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 66

Quick Links: